The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?
Abstract
The bone-seeking, α-particle-emitting radiopharmaceutical Alpharadin, 223RaCl2 (half-life = 11.4 days), is under clinical development as a novel treatment for skeletal metastases from breast and prostate cancer. This article summarizes the current status of preclinical and clinical research on 223RaCl2. Potential advantages of 223Ra to that of external beam irradiation and registered β-emitting bone seekers are discussed. Published data of 223Ra dosimetry in mice and a therapeutic study in a skeletal metastases model in nude rats have indicated significant therapeutic potential of bone-seeking α-emitters. This article provides short-term and long-term results from the first clinical single dosage trial. We also present data from a repeated dosage study of five consecutive injections of 50 kBq/kg body weight, once every 3rd week, or two injections of 125 kBq/kg body weight, 6 weeks apart. Furthermore, interim results are described for a randomized phase 2 trial involving 64 patients with hormone-refractory prostate cancer and painful skeletal metastases who received four monthly injections of 223Ra or saline as an adjuvant to external beam radiotherapy. Lastly, we present preliminary dose estimates for 223Ra in humans. Results indicate that repeated dosing is feasible and toxicity is low, and that opportunities are available for combined treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Task Group of Committee 2 (1995) · Annals of the ICRP · doi:10.1016/s0146-6453(00)80008-1 · Cited by 1,369
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084
Malignant bone pain: pathophysiology and treatment
Mercadante, S. (1997) · Pain · doi:10.1016/s0304-3959(96)03267-8 · Cited by 861
Steenland, E., Leer, J., van Houwelingen, H., Post, W. J., van den Hout, W. B., Kievit, J., de Haes, H., Martijn, H., Oei, B., Vonk, E., et al. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00110-3 · Cited by 677
Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-712_4 · Cited by 646
Wu, J. S.-Y., Wong, R., Johnston, M., Bezjak, A., & Whelan, T. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)04147-0 · Cited by 601
Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Sathyanarayana, J. R., Yakemchuk, V. N., Thomas, G. M., Erlich, L. E., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90309-j · Cited by 534
Bone metastases: pathophysiology and management policy.
Nielsen, O. S., Munro, A. J., & Tannock, I. F. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.509 · Cited by 486
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Cited by
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationSgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Self-citationTargeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy
Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A.-K., Ramdahl, T., Flux, G. D., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/10/3207 · Cited by 122
Metadata
- Authors
- Bruland, Ø. S., Nilsson, S., Fisher, D. R., & Larsen, R. H.
- Venue
- Clinical Cancer Research
- Published
- 2006-10-15
- Volume
- 12
- Issue
- 20
- Pages
- 6250s-6257s
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2147376175
- Cited by
- 357
- References
- 37
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-0841
- The paper
- Bruland, Ø. S., Nilsson, S., Fisher, D. R., & Larsen, R. H. (2006). High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-0841
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
